多替阿巴拉米片上市的时间

It is a once-daily three-in-one drug developed by ViiV Healthcare, a joint venture between GlaxoSmithKline and Pfizer. The drug is based on the treatment plan of the integrase inhibitor Tivicay (Dolutegravir) and also contains two nucleoside reverse transcriptase inhibitors, Abacavir and Lamivudine. It was approved by the FDA on August 27, 2014.

On January 22, 2018, GlaxoSmithKline (GSK) announced that its single-tablet compound preparation dolutegravir (Triumeq), which is based on the new generation integrase inhibitor dolutegravir (DTG) and is used to treat HIV, was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China.

For adults and adolescents, the recommended dose of Dolutegra is one tablet once daily. Adults or adolescents whose body weight is less than 40 kg should not be given this product because this product is a fixed-dose tablet and the dose cannot be reduced. Dolutegravir is a fixed-dose tablet and should not be used in patients requiring dose adjustments. If discontinuation or dose adjustment of one of the active ingredients is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these circumstances, physicians should refer to the respective product information for these medicines. If the patient misses a dose of Docetaxel, and it is more than 4 hours before the next dose, Docetaxel should be taken as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule. There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients aged ≥65 years, and there is no evidence that older patients require different doses than younger adults. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group.

Adverse reactions include gastrointestinal - nausea, vomiting, diarrhea, abdominal pain, mouth ulcers; neurology/psychiatry - headache, paresthesia; hematology - lymphopenia; liver/pancreas - increased liver function indicators; muscle and bone - myalgia, myolysis, arthralgia, increased creatine phosphatase; respiratory - dyspnea, sore throat, cough, influenza-like syndrome; skin - rash (usually maculopapular and urticaria); urology - Elevated creatinine, renal failure; other - fever, drowsiness, malaise, edema, lymphadenopathy, hypotension, conjunctivitis, allergies.